CA2440588A1 - Chronotherapeutic dosage forms - Google Patents

Chronotherapeutic dosage forms Download PDF

Info

Publication number
CA2440588A1
CA2440588A1 CA002440588A CA2440588A CA2440588A1 CA 2440588 A1 CA2440588 A1 CA 2440588A1 CA 002440588 A CA002440588 A CA 002440588A CA 2440588 A CA2440588 A CA 2440588A CA 2440588 A1 CA2440588 A1 CA 2440588A1
Authority
CA
Canada
Prior art keywords
dosage form
delayed release
oral solid
solid dosage
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002440588A
Other languages
French (fr)
Other versions
CA2440588C (en
Inventor
Anand R. Baichwal
Paul Woodcock
Raymond Higgins
Jaclyn Cobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penwest Pharmaceuticals Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2440588A1 publication Critical patent/CA2440588A1/en
Application granted granted Critical
Publication of CA2440588C publication Critical patent/CA2440588C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A chronotherpautic pharmaceutical formulation comprising a core containing a n active agent (e.g. drug) and a delayed release compression coating comprisin g a natural or synthetic gum applied onto the surface of the core.

Claims (57)

1. A delayed release oral solid dosage form, comprising a core comprising a therapeutically effective amount of a drug, and a delayed release material compression coated onto said core, said delayed release material comprising one or more natural or synthetic gums, said compression coating delaying the release of said drug from said dosage form until after a period of time from about 2 to about 18 hours after exposure of the dosage form to an aqueous solution.
2. The delayed release oral solid dosage form of claim 1, wherein said one or more natural or synthetic gums are agglomerated with a saccharide material prior to being compression coated onto said core.
3. The delayed release oral solid dosage form of claim 1, which delays release of said drug until at least about 4 hours after exposure of the dosage form to an aqueous solution.
4. The delayed release oral solid dosage form of claim 1, wherein said gums comprise a mixture of xanthan gum and locust bean gum.
5. The delayed release oral solid dosage form of claim 4, wherein said delayed release material further comprises an ionizable gel strength enhancing agent selected from the group consisting of calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, sodium fluoride, and mixtures thereof.
6. The delayed release oral solid dosage form of claim 5, wherein said ionizable gel strength enhancing agent is calcium sulfate.
7. The delayed release oral solid dosage form of claim 1, wherein said delayed release material further comprises a surfactant selected from the group consisting of anionic surfactants, cationic surfactants, amphoteric (amphipathic/ amphophilic) surfactants, and non-ionic surfactants.
8. The delayed release oral solid dosage form of claim 1, wherein said delayed release material further comprises a hydrophobic material.
9. The delayed release oral solid dosage form of claim 8, wherein said hydrophobic material is selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic acid esters, waxes, shellac, zero, hydrogenated vegetable oil, and mixtures thereof, in an amount effective to slow the hydration of said gelling agent when exposed to an environmental fluid.
10. The delayed release oral solid dosage form of claim 10, wherein said hydrophobic material comprises ethylcellulose.
11. The delayed release oral solid dosage form of claim 2, wherein said saccharide is selected from the group consisting of sucrose, dextrose, lactose, fructose, mannitol, and mixtures thereof.
12. The delayed release oral solid dosage form of claim 1, wherein said core further comprises from about 5 to about 20 percent disintegrant, by weight.
13. The delayed release oral solid dosage form of claim 12, wherein said disintegrant is a superdisintegrant.
14. The delayed release oral solid dosage form of claim 12, wherein said disintegrant is selected from the group consisting of starch, veegum, crospovidone, cellulose, kaolin, microcrystalline cellulose, crosslinked polyvinyl pyrrolidone, and mixtures thereof.
15. The delayed release oral solid dosage form of claim 13, wherein said superdisintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, crosslinked carboxy methyl cellulose, sodium starch glycolate, and mixtures thereof.
16. The delayed release oral solid dosage form of claim 1, wherein said inner core further comprises an inert diluent selected from the group consisting of sucrose, dextrose, lactose, microcrystalline cellulose, fructose, xylitol, sorbitol, mannitol, starches, mixtures thereof.
17. The delayed release oral solid dosage form of claim 1, wherein said core is an immediate release core.
18. The delayed release oral solid dosage form of claim 1, wherein said core is further comprises a sustained release carrier.
19. A delayed release oral solid dosage form comprising:
a core comprising a therapeutically effective amount of a drug, and an agglomerated delayed release material compression coated onto said core, said agglomerated delayed release material comprising a gum selected from the group consisting of a homopolysaccharide, a heteropolysaccharide, and a mixture of a homopolysaccharide and a heteropolysaccharide, together with a pharmaceutically acceptable excipient, said compression coating delaying the release of said drug from said dosage form for a predetermined period of time after exposure of the dosage form to an aqueous solution.
20. The delayed release oral solid dosage form of claim 1, wherein said heteropolysaccharide gum is in an amount of from about 20 to about 80 percent of the delayed release coating and said homopolysaccharide gum is in an amount of from about 80 to about 20 percent of the delayed release coating.
21. The delayed release oral solid dosage form of claim2l, wherein said heteropolysaccharide gum is xanthan gum and said homopolysaccharide gum is locust bean gum.
22. The delayed release oral solid dosage form of claim 20, wherein said core further comprises an effective amount of disintegrant.
23. A delayed release oral solid dosage form comprising:
a core comprising a therapeutically effective amount of a drug and an effective amount of a disintegrant, and an agglomerated delayed release material compression coated onto said core, said agglomerated delayed release material consisting essentially of one or more natural or synthetic pharmaceutically acceptable gums and one or more optional pharmaceutical excipients, said compression coating delaying the release of said drug from said dosage form for a predetermined period of time after exposure of the dosage form to an aqueous solution.
24. The delayed release oral solid dosage form of claim 23, wherein said core comprises from about 5 to about 20 percent disintegrant, by weight.
25. The delayed release oral solid dosage form of claim 24, wherein said disintegrant is selected from the group consisting of starch, veegum, crospovidone, cellulose, kaolin, microcrystalline cellulose, crosslinked polyvinyl pyrrolidone, and mixtures thereof.
26. The delayed release oral solid dosage form of claim 24, wherein said disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, crosslinked carboxy methyl cellulose, sodium starch glycolate, and mixtures thereof.
27. The delayed release oral solid dosage form of claim 22 which delays the release of said drug until at least about 4 hours after exposure of the dosage form to an aqueous solution.
28. The delayed release oral solid dosage form of claim 22, wherein said gums comprise a mixture of xanthan gum and locust bean gum.
29. A delayed release oral solid dosage form comprising:
a core comprising a therapeutically effective amount of a drug and a disintegrant, and a delayed release material compression coated onto said core, said delayed release material comprising one or more natural or synthetic gums, said compression coating delaying the release of said drug from said dosage form for a predetermined period of time after exposure of the dosage form to an aqueous solution, said disintegrant being included in said core in an amount effective to cause the release of at least about 50 percent of said drug into said aqueous solution within one hour after said predetermined period of time.
30. The delayed release oral solid dosage form of claim 29, wherein said disintegrant comprises from about 5 to about 20 percent of said core, by weight.
31. The delayed release oral solid dosage form of claim 29, wherein said disintegrant comprises from about about 0.1 to about 5 percent of said oral solid dosage form, by weight.
32. The delayed release oral solid dosage form of claim 29, wherein said disintegrant is a superdisintegrant.
33. The delayed release oral solid dosage form of claim 32, wherein said superdisintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, crosslinked carboxy methyl cellulose, sodium starch glycolate, and mixtures thereof.
34. The delayed release oral solid dosage form of claim 29, wherein said gums comprise a mixture of xanthan gum and locust bean gum.
35. The delayed release oral solid dosage form of claim 34, wherein said xanthan gum and said locust bean gum are agglomerated with a saccharide material prior to compression coating onto said core.
36. A delayed release oral solid tablet, comprising:

a tablet core comprising a therapeutically effective amount of a drug, and a delayed release material compression coated onto said core, said delayed release material comprising one or more natural or synthetic gums, said gums comprising from about 6.5 percent to about 83 percent of the tablet by weight, said compression coating delaying the release of said drug from said dosage form for a period of time from about 2 to about 18 hours after exposure of the dosage form to an aqueous solution.
37. The delayed release oral solid tablet of claim 36, wherein said tablet core further comprises from about 5 to about 20% superdisintegrant.
38. A chronotherapeutic, delayed release oral solid dosage form for a low dose drug, comprising a core comprising from about 0.01 mg to about 40 mg drug together with optional pharmaceutically acceptable excipients, and a delayed release material compression coated onto said core, said delayed release material comprising one or more natural or synthetic gums, said compression coating comprising from about 75 to about 94 percent by weight of the oral solid dosage form, and the ratio of the core to gum in said compression coating being from about 1:0.37 to about 1:5, by weight, said compression coating delaying the release of said drug from said dosage form for a period of time from about 2 to about 18 hours after exposure of the dosage form to an aqueous solution.
39. The oral solid dosage form of claim 38, wherein the total weight of said dosage form is from about 220 mg to about 900 mg.
40. The oral solid dosage form of claim 38, wherein the core weight is from about 50 mg to about 170 mg.
41. The oral solid dosage form of claim 38, wherein said core is from about 5 to about 23 percent by weight of the total weight of the dosage form.
42. The oral solid dosage form of claim 38, wherein said compression coating is from about 150 mg to about 850 mg.
43. The oral solid dosage form of claim 38, wherein said coating is from about 78 to 80 percent by weight of the total weight of the dosage form.
44. The oral solid dosage form of claim 38, wherein the ratio of the core to gum in the compression coating is from about 1:0.37 to about 1:1.12, most preferably from about 1:0.75.
45. The oral solid dosage form of claim 38, wherein the ratio of the core to compression coating is preferably from about 1:2 to about 1:9, by weight.
46. A chronotherapeutic, delayed release oral solid dosage form for a relatively high dose drug, comprising a core comprising from about 41 mg to about 300 mg of a drug, and a delayed release material compression coated onto said core, said delayed release material comprising one or more natural or synthetic gums, the ratio of the core to gum in said compression coating being from about 1:0.3 to about 1:3, by weight, the total weight of said oral solid dosage form being from about 500 mg to about 1500 mg, said compression coating delaying the release of said drug from said dosage form for a period of time from about 2 to about 18 hours after exposure of the dosage form to an aqueous solution.
47. The oral solid dosage form of claim 46, wherein the ratio of the core to gum in said compression coating is from about 1:0.6 to about 1:1.5, by weight.
48. The oral solid dosage form of claim 46, wherein the ratio of the core to compression coating is from about 1:1 to about 1:5, by weight.
49. The oral solid dosage form of claim 46, wherein the ratio of the core to compression coating is from about 1:2 to about 1:3.
50. The oral solid dosage form of claim 46, wherein the total weight of the dosage form is from about 750 mg to about 1000 mg.
51. A method of preparing a chronotherapeutic oral solid dosage form of a drug, comprising:
preparing a core comprising a therapeutically effective amount of a drug and from about 5 to about 20% disintegrant, by weight of the core, preparing a granulate of a delayed release material comprising one or more natural or synthetic gums, compression coating said granulate onto said core, said compression coating delaying the release of said drug from said dosage form until after a period of time from about 2 to about 18 hours after exposure of the dosage form to an aqueous solution.
52. The method of claim 51, further comprising preparing said granulate of delayed release material by wet granulating one or more natural or synthetic gums together with at least one pharmaceutically acceptable excipient, and drying the resultant granulate to obtain agglomerated particles of said delayed release material.
53. The method of claim 52, further comprising granulating said drug, said disintegrant, and a pharmaceutically acceptable inert diluent prior to said compression coating step.
54. The method of claim 53, wherein said disintegrant is a superdisintegrant incorporated into said core in an amount said disintegrant being included in said core in an amount effective to cause the release of at least about 50 percent of said drug into said aqueous solution within one hour upon completion of the time period for said delayed release.
55. The use of the oral solid dosage form of claims 1, 19, 23, 29, 36, 38 or in the preparation of a chronotherapeutic medicament, which delays release of said drug until at least about 4 hours after exposure of the dosage form to gastrointestinal fluid.
56. The oral solid dosage form claim 55, wherein after oral administration of the dosage form, the drug is not released from the dosage form for about 4 to about 12 hours.
57. The oral solid dosage form of claim 55, wherein after oral administration of the dosage form, the drug is released over a time period of at least about 4 hours after the period of delay is completed.
CA2440588A 2001-03-13 2002-03-13 Chronotherapeutic dosage forms Expired - Fee Related CA2440588C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27538201P 2001-03-13 2001-03-13
US60/275,382 2001-03-13
PCT/US2002/007936 WO2002072034A2 (en) 2001-03-13 2002-03-13 Chronotherapeutic dosage forms

Publications (2)

Publication Number Publication Date
CA2440588A1 true CA2440588A1 (en) 2002-09-19
CA2440588C CA2440588C (en) 2010-02-09

Family

ID=23052055

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2440588A Expired - Fee Related CA2440588C (en) 2001-03-13 2002-03-13 Chronotherapeutic dosage forms
CA002440641A Abandoned CA2440641A1 (en) 2001-03-13 2002-03-13 Chronotherapeutic dosage forms containing glucocorticosteroid

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002440641A Abandoned CA2440641A1 (en) 2001-03-13 2002-03-13 Chronotherapeutic dosage forms containing glucocorticosteroid

Country Status (15)

Country Link
US (4) US20030190360A1 (en)
EP (2) EP1368000A4 (en)
JP (3) JP2004529902A (en)
KR (1) KR20040047747A (en)
CN (1) CN1499960A (en)
AP (1) AP1748A (en)
AU (2) AU2002244295B2 (en)
CA (2) CA2440588C (en)
EA (1) EA008224B1 (en)
ES (1) ES2436523T3 (en)
HU (1) HUP0501071A3 (en)
IL (3) IL157633A0 (en)
MX (2) MXPA03008292A (en)
NZ (1) NZ527832A (en)
WO (2) WO2002072034A2 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
ES2436523T3 (en) * 2001-03-13 2014-01-02 Endo Pharmaceuticals Inc. Therapeutic dosage forms
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE10255106A1 (en) * 2002-11-24 2004-06-09 Novosom Ag Liposomal glucocorticoids
MXPA05011446A (en) 2003-04-24 2006-05-31 Jagotec Ag Delayed release tablet with defined core geometry.
US20070148229A1 (en) * 2003-04-24 2007-06-28 Jagotec Ag Tablet with coloured core
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (en) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (en) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP2007513869A (en) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
EP1663156A2 (en) * 2003-09-19 2006-06-07 Penwest Pharmaceuticals Company Chronotherapeutic dosage forms
MXPA06003100A (en) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Delayed released dosage forms.
US20050238731A1 (en) * 2003-12-29 2005-10-27 Stephen Holt Composition and method for treating the effects of diseases and maladies of the upper digestive tract
JP2007522203A (en) * 2004-02-11 2007-08-09 アスファーマ・リミテッド Time therapy compositions and methods of their use
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US9925139B2 (en) 2004-04-22 2018-03-27 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
KR101363563B1 (en) * 2004-09-10 2014-02-14 자고텍 아게 Tablets with site and time-controlled gastrointestinal release of active ingredient
DE102004043863A1 (en) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with local and time-controlled drug release in the gastrointestinal tract
AU2011232809B2 (en) * 2004-09-10 2014-03-20 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
EP1990049A3 (en) * 2005-03-21 2008-11-26 Vicus Therapeutics SPE 1, LLC Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID)
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EA015304B1 (en) 2006-08-03 2011-06-30 Нитек Фарма Аг Delayed-release glucocorticoid treatment of rheumatoid disease
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008079868A1 (en) * 2006-12-22 2008-07-03 Drugtech Corporation Clonidine composition and method of use
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8299122B2 (en) * 2008-04-14 2012-10-30 Skinvisible Pharmaceuticals, Inc. Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX339136B (en) * 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Pulsed-release sildenafil composition and method for preparing said composition.
JP2012515765A (en) * 2009-01-22 2012-07-12 アボット ヘルスケア プライベート リミテッド Pharmaceutical composition for time treatment
WO2010084188A1 (en) 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2561892B1 (en) * 2010-03-31 2015-05-06 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
ES2661089T3 (en) 2010-07-20 2018-03-27 Halozyme Inc. Methods of treatment or prevention of adverse side effects associated with the administration of an anti-hyaluronan agent
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
KR101572336B1 (en) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 Encased tamper resistant controlled release dosage forms
CN103327969A (en) 2010-12-23 2013-09-25 普渡制药公司 Tamper resistant solid oral dosage forms
KR101870004B1 (en) 2011-09-30 2018-06-22 모찌다 세이야쿠 가부시끼가이샤 Easy-to-take solid preparation
RU2471479C1 (en) * 2012-02-13 2013-01-10 Общество с ограниченной ответственностью "Агентство редких лекарств и технологий" Tableted pharmaceutical composition containing dexamethasone as active ingredient for oral administration, and method for preparing it
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
TW201400146A (en) * 2012-06-05 2014-01-01 Takeda Pharmaceutical Core-containing tablet
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
EA201500742A1 (en) 2013-02-05 2015-12-30 Пердью Фарма Л.П. PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
WO2014132215A1 (en) * 2013-02-28 2014-09-04 Lupin Limited Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
MX2015011099A (en) * 2013-02-28 2016-04-06 Lupin Ltd Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2986280B1 (en) 2013-04-16 2021-03-17 Murray & Poole Enterprises, Ltd. Sustained-release formulations of colchicine and methods of using same
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP3041463A1 (en) 2013-09-02 2016-07-13 Sun Pharmaceutical Industries Ltd Pulsatile-release dosage form
EA201690732A1 (en) 2013-10-10 2016-12-30 Синерджи Фармасьютикалз, Инк. GUANILATZIKLAZY AGONISTS USED FOR THE TREATMENT OF OPIOID-INDUCED DYSFUNCTIONS
US20180071272A1 (en) * 2014-10-23 2018-03-15 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
EA201791225A1 (en) * 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. COMPOSITIONS AND METHODS OF APPLICATION OF SOLABEGRON WITH MODIFIED RELIEF AT THE SYMPTOMS OF THE LOWER BLANK
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
CN108884130B (en) 2016-01-11 2022-09-13 博士医疗爱尔兰有限公司 Formulations and methods for treating ulcerative colitis
EP3463307A4 (en) * 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN207648424U (en) 2017-07-17 2018-07-24 手持产品公司 Equipment holding mechanism
WO2019040748A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
JP7467884B2 (en) 2019-10-29 2024-04-16 オムロンヘルスケア株式会社 Sphygmomanometer, method of operating the same, and program
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
CN114588124B (en) * 2020-12-07 2023-10-20 江苏恒瑞医药股份有限公司 Delayed release pharmaceutical composition
AU2022209123A1 (en) 2021-01-15 2023-07-06 Galventa Ag Pulsatile release caffeine formulation
CN114712319B (en) * 2022-03-25 2024-01-09 北京诺康达医药科技股份有限公司 Felodipine and propranolol hydrochloride compound preparation and preparation method thereof

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US4248858A (en) 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
FR2471186A1 (en) 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
US4851231A (en) 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
SE457505B (en) 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
DK62184D0 (en) 1984-02-10 1984-02-10 Benzon As Alfred DIFFUSION COATED POLYDEPOT PREPARATION
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4853249A (en) * 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1188212B (en) 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
JPS62195323A (en) 1986-02-24 1987-08-28 Eisai Co Ltd Gastric resident particle
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
IT1204294B (en) 1986-03-11 1989-03-01 Gentili Ist Spa METHOD OF MANUFACTURE OF GRANULARS SUITABLE FOR THE PRODUCTION OF COATED TABLETS, FOR ORAL USE, WITH CONTROLLED RELEASE
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IE58401B1 (en) 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
SE460945B (en) 1987-01-15 1989-12-11 Lejus Medical Ab A MULTIPLE-UNIT DOS COMPOSITION OF FUROSEMID
GB8702411D0 (en) 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
NO883326L (en) * 1987-08-11 1989-02-13 Bayer Ag DHP-retard-COOK.
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US4841231A (en) 1987-10-30 1989-06-20 Unisys Corporation Test probe accessibility method and tool
US4971805A (en) 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
JPH0768125B2 (en) 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
US4857337A (en) 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
US5468746A (en) * 1988-07-29 1995-11-21 Zambon Group S.P.A. Compounds active on the cardiovascular system
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5169639A (en) 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5334372A (en) 1988-10-07 1994-08-02 Kao Corporation Alcohol-modified silicon ester derivative and cosmetic composition containing same
IT1230576B (en) 1988-10-20 1991-10-28 Angeli Inst Spa ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON
IT1227899B (en) 1988-12-23 1991-05-14 Poli Ind Chimica Spa TOTAL OR PARTIAL COATING OF PHARMACEUTICAL ACTIVE SUBSTANCES AND RELATED COMPOSITIONS
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5032406A (en) 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5198227A (en) 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
IT1241417B (en) 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP2773959B2 (en) 1990-07-10 1998-07-09 信越化学工業株式会社 Colon release solid preparation
US5202338A (en) 1990-10-31 1993-04-13 Vilmos Bar Dihydroquinoline derivatives, pharmaceutical compositions and methods of use of dihydroquinoline derivatives as modulators of the arachidonic acid cascade
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
IT1251153B (en) * 1991-08-06 1995-05-04 Vectorpharma Int SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION HAVING PROHIBITED GASTRIC RESIDENCE
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
IT1260505B (en) 1992-06-01 1996-04-09 Poli Ind Chimica Spa ORAL PHARMACEUTICAL SYSTEMS WITH DELAYED DELIVERY FOR THE SPECIFIC RELEASE IN THE COLON
US5262172A (en) 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
NL9201195A (en) 1992-07-03 1994-02-01 Tno PREPARATION FOR THE REGULATED DELIVERY OF AN ACTIVE SUBSTANCE AND METHOD FOR PREPARING SUCH A PREPARATION.
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
JPH072650A (en) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd Release part control type preparation
JPH09500645A (en) 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー Controlled release tacrine drug delivery system and method of making same
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5399358A (en) 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5407687A (en) 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5374759A (en) 1994-03-22 1994-12-20 Siltech Inc. Silicone esters of hydroxy acid
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO1997026865A1 (en) 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
MX9801835A (en) 1996-07-08 1998-08-30 Mendell Co Inc Edward Sustained release matrix for high-dose insoluble drugs.
US5792476A (en) 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
DE19709532A1 (en) * 1997-03-10 1998-09-17 Basf Ag Use of redispersible polymer powders or polymer granules for coating pharmaceutical or agrochemical dosage forms
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
RU2236847C2 (en) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Composition as multiple particles with modified release
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
ES2436523T3 (en) * 2001-03-13 2014-01-02 Endo Pharmaceuticals Inc. Therapeutic dosage forms

Also Published As

Publication number Publication date
ES2436523T3 (en) 2014-01-02
AU2002244295B2 (en) 2006-02-09
EP1368000A4 (en) 2004-12-01
AP2003002865A0 (en) 2003-09-30
AU2002252364B2 (en) 2005-08-25
EP1368005B1 (en) 2013-08-21
EA200300999A1 (en) 2004-02-26
EP1368005B9 (en) 2014-06-11
CA2440641A1 (en) 2002-09-19
EP1368000A2 (en) 2003-12-10
US20030082230A1 (en) 2003-05-01
EP1368005A2 (en) 2003-12-10
JP2005500255A (en) 2005-01-06
EP1368005A4 (en) 2004-12-01
AP1748A (en) 2007-06-11
WO2002072033A3 (en) 2003-03-13
IL157633A0 (en) 2004-03-28
CA2440588C (en) 2010-02-09
EA008224B1 (en) 2007-04-27
KR20040047747A (en) 2004-06-05
JP5005157B2 (en) 2012-08-22
HUP0501071A2 (en) 2007-02-28
US20030190360A1 (en) 2003-10-09
JP2004529902A (en) 2004-09-30
WO2002072034A3 (en) 2002-11-21
JP5232062B2 (en) 2013-07-10
WO2002072033A2 (en) 2002-09-19
US20050276853A1 (en) 2005-12-15
US7887841B2 (en) 2011-02-15
US20110217336A1 (en) 2011-09-08
IL157634A0 (en) 2004-03-28
CN1499960A (en) 2004-05-26
MXPA03008292A (en) 2003-12-11
JP2009149691A (en) 2009-07-09
IL157633A (en) 2011-06-30
MXPA03008293A (en) 2003-12-11
NZ527832A (en) 2006-03-31
HUP0501071A3 (en) 2007-06-28
WO2002072034A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
CA2440588A1 (en) Chronotherapeutic dosage forms
AU2009335766B2 (en) Extended-release pharmaceutical formulations
EP1025841B1 (en) Bilayered amoxycillin tablets
EP0881899B1 (en) Dosage form of ibuprofen
US8535717B2 (en) Pharmaceutical composition
KR101046894B1 (en) Dosage Form of Sodium Ibuprofen
US8617601B2 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
JP2011098964A5 (en)
JP2008507508A (en) Topiramate sustained-release preparation and method for producing the same
JPH02240017A (en) Gemfibrozyl composition with improved releasing property
US20100160363A1 (en) Extended-release pharmaceutical formulations
KR20010086062A (en) Sustained release matrix systems for highly soluble drugs
MX2012015091A (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-m ethylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.
EP1909777A2 (en) High drug load formulations and dosage forms
JP5517327B2 (en) Composition for orally disintegrating tablets
EP0749308A1 (en) Film coated tablet of paracetamol and domperidone
JP2005508901A (en) Dosage form for sustained release of active ingredient
CA2449520A1 (en) Swallow tablet comprising paracetamol
WO2015132341A1 (en) Pharmaceutical formulations of vildagliptin
WO2012029838A1 (en) Orally disintegrating tablet
US20090155369A1 (en) Pharmaceutical composition containing levodopa, entacapone and carbidopa
JPH0757726B2 (en) Sustained release tablets based on high molecular weight hydroxypropyl methylcellulose
US20080020042A1 (en) Dosage form of sodium ibuprofen
US20060099262A1 (en) Methods and formulations for making controlled release oral dosage form
JP2023036924A (en) Pharmaceutical composition containing lenalidomide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190313